PPM1D and myelodysplastic syndrome: Patients suffering from therapy-induced malignancies (mainly t-AML and myelodysplastic syndrome) show increased frequency of truncating PPM1D mutations and we have recently reported similar phenotype in transgenic mice [32, 33, 66].